The increasing demand for GLP-1 receptor agonists is fueling competition with more pharmaceutical companies working on new drugs in this space. As additional treatment options enter the market, prices may eventually decrease, making these medications more accessible to a broader population. In the meantime, efforts like Lilly’s expanded Zepbound access program are a small but meaningful step in the right direction.

Insurance coverage is one of the biggest barriers to receiving obesity medication. Medicare does not cover anti-obesity medications at all, viewing them as cosmetic drugs. Most state-Medicaid plans do not cover them either. Private insurances vary in their rates of coverage, and most require a prior authorization before the drug is covered. It is helpful for patients seeking weight loss treatment to be aware of their coverage options, particularly when switching health plans.